CD28
癌症研究
癌症免疫疗法
T细胞
免疫系统
细胞因子
癌细胞
化学
抗体
细胞生物学
免疫疗法
癌症
外周血单个核细胞
Jurkat细胞
体外
细胞毒性T细胞
生物
细胞
细胞生长
双特异性抗体
免疫学
启动(农业)
共刺激
抑制器
分子生物学
免疫检查点
CD3型
肿瘤微环境
细胞培养
髓源性抑制细胞
作者
Thomas Thisted,F. Donelson Smith,Zhi-Gang Jiang,Zuzana Biesová,Adejumoke M. Onumajuru,Yuliya Kleschenko,Kanam Malhotra,Vikas Saxena,Arnab Mukherjee,Edward Htun van der Horst
标识
DOI:10.1158/2326-6066.cir-25-0535
摘要
Reinvigoration of tumor-reactive T cells using costimulatory bispecific antibodies (bsAb) targeting CD28 is emerging as a promising therapeutic strategy. Conditional, tumor-specific recruitment can offer a layer of control and specificity. We developed pH-selective CD28xV-domain Ig-containing suppressor of T-cell activation (VISTA) bsAbs to act specifically within the acidic tumor microenvironment, aiming for enhanced T cell-mediated cancer cell killing while minimizing systemic T-cell activation and cytokine release syndrome risk. CD28 agonism by our CD28xVISTA bsAbs relies on pH-selective engagement of VISTA, a protein robustly expressed on myeloid cells abundant in most solid tumors. Our lead candidate displayed pH-dependent engagement of VISTA and simultaneous binding to CD28, resulting in VISTA-dependent CD28 signaling in a reporter cell line. CD28xVISTA avidly binds VISTA+ cells, and costimulatory activity was shown in vitro by its ability to activate and expand T cells and enhance T cell-mediated cancer cell killing in cocultures of human peripheral blood mononuclear cells and cancer cells in the presence of a tumor-associated antigen-targeted anti-CD3 T-cell engager. This CD28xVISTA bsAb efficiently inhibited the growth of human VISTA-expressing MC38 tumors in a humanized CD28 syngeneic mouse model in combination with PD-1 blockade. Our findings support signaling both in cis (between T cell and target cell displaying peptide-MHC complex) and in trans, with stimulation occurring through CD28 clustering outside of the immune synapse. This CD28xVISTA bsAb showed no signs of superagonistic properties in several in vitro cytokine release syndrome assays. Thus, our data support clinical development for solid tumors in combination with anti-PD-1 or tumor-associated antigen-targeted anti-CD3 T-cell engagers.
科研通智能强力驱动
Strongly Powered by AbleSci AI